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The discovery of SNCA mutations pathogenic for au-
tosomal-dominant Lewy body Parkinson’s disease
(PD) in 1997 heralded a revolution in understanding
the molecular and genetic basis of PD. Indeed, it now
is clear that Lewy body PD is one of many neurode-
generative parkinsonian disorders that result from ni-
grostriatal degeneration caused by diverse mecha-
nisms. However, to capitalize on these new insights
and facilitate efforts to improve the diagnosis and
therapy of neurodegenerative movement disorders, it
is timely to define a nosology for these diseases that
is based on their genetic and molecular underpin-
nings, as proposed here.
If it looks like a duck, and quacks like a duck, we have
at least to consider the possibility that we have a small
aquatic bird of the family anatidae on our hands.
—Douglas Adams, 1952–2001, The Hitchhiker’s Guide
to the Galaxy
In 1817, James Parkinson described the disease that
bears his name (Parkinson, 1817), and almost 100 years
later, Friedrich Lewy described the Lewy body that has
become synonymous with PD (Lewy, 1912). The central
role of the Lewy body pathology in PD was elucidated
with the identification of mutations in the SNCA (α-synu-
clein) gene and the demonstration that α-synuclein is
the principal component of Lewy bodies (Polymer-
opoulos et al., 1997; Spillantini et al., 1997). However,
since 1997, mutations were identified in at least five
additional genes in familial PD kindreds, and numerous
additional genes and genetic loci are also implicated
(Table 1) (Cookson, 2005; Feany, 2004). Thus, while ni-
grostriatal degeneration is the common pathological
substrate of all of these forms of parkinsonism, Lewy
bodies are not present in the brains of all patients with
sporadic or familial PD (Figure 1). And, more impor-
tantly, how these fibrillar aggregates of misfolded α-synu-
clein induce neurodegeneration is a matter of intense
debate, in part because the normal function of α-synu-
clein remains unknown. Thus, we review the relation-
ship of PD and other parkinsonian disorders to Lewy
bodies, and we emphasize that clarity about the rela-
tionship of disease mechanisms and phenotype has a
powerful impact on the development of therapies that
target distinct pathogenetic processes underlying the*Correspondence: trojanow@mail.med.upenn.educlinical expression of this etiologically diverse group
of disorders.
Lewy body PD, the most common neurodegenerative
movement disorder, increases steadily with age, affect-
ing w1% of the population at age 65 and up to 5% of
the population by the age of 85. The clinical phenotype
of Lewy body PD is characterized by L-dopa-respon-
sive motor impairments including bradykinesia, in-
creased muscle tone, resting tremor, and abnormal
postural righting reflexes, as originally described by
Parkinson (1817). However, the clinical phenotype of
Lewy body PD overlaps significantly with several pre-
viously described and newly reported parkinsonian
syndromes, and rigorous diagnostic criteria have there-
fore been established for both practical and research
purposes (Gelb et al., 1999). Nonetheless, the accuracy
of a clinical diagnosis of PD is only w90% even in pa-
tients who are followed longitudinally, and definitive di-
agnosis requires postmortem neuropathological exami-
nation (Hughes et al., 2001).
The identification of SNCA mutations in two kindreds
with autosomal-dominant PD (Polymeropoulos et al.,
1997) and the subsequent identification of fibrillar
α-synuclein as the principal component of Lewy body
pathology (Spillantini et al., 1997) were consistent with
the concept that the Lewy body defined classic PD.
This notion was supported by the subsequent identifi-
cation of additional SNCA mutations and Lewy body
pathology in kindreds with other clinical manifestations
of disease ranging from typical PD to parkinsonism
with concurrent dementia known as Parkinson’s disease
dementia and dementia with Lewy bodies. Each of
these clinical entities is characterized by widespread
Lewy bodies and related α-synuclein pathologies such
as dystrophic neurites (Kruger et al., 1998; Singleton et
al., 2003; Zarranz et al., 2004). Thus, these discoveries
dramatically changed concepts of the role of Lewy
bodies in mechanisms of disease. Indeed, while Lewy
bodies were widely recognized as distinct eosinophilic
intraneuronal cytoplasmic inclusions formed by a star-
burst array of densely packed 10–20 nm diameter fila-
ments frequently displacing the nucleus, whether or not
their significance to PD extended beyond their role as
a diagnostic marker was long debated. However, it is
now clear that the deposition of pathological α-synu-
clein fibrils into inclusions known as Lewy bodies or
Lewy neurites not only results in the formation of diag-
nostic signatures of PD and related synucleinopathies,
but that these pathologies also are integral to the onset
and progression of these disorders. Moreover, while
Lewy bodies were most readily detected in the neuro-
melanin-containing neurons of the pars compacta,
immunohistochemistry for α-synuclein demonstrated a
more widespread distribution of pathology emphasiz-
ing the oft-neglected point that, while the nigrostriatal
system is the first and most common region that un-
dergoes neurodegeneration in PD, multiple additional
brain regions always are affected in these disorders so
that their clinical manifestations commonly extend be-
yond those attributable to the nigrostriatal system
alone.
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Chromosomal
Locus Location Gene/Protein Inheritance Pattern Clinical Phenotype
PARK1 4q21 SNCA/α-synuclein 1. ADd typical PD ± dementia
2. genetic susceptibility
PARK2 6q25-27 PARK2/parkin 1. ARd juvenile onset PD; atypical features
2. genetic susceptibility
PARK3 2p13 unknown ADa typical PD
PARK5 4p14 UCHL1b AD typical PD
PARK6 1p35-36 PINK1 AR early onset PD; slow progression
PARK7 1p36 PARK7/DJ-1 AR early onset PD; slow progression
PARK8 12p11.2-13.1 LRRK2/dardarin AD typical PD ± dementia &
amyotrophy
PARK10b 1p32 unknown genetic susceptibility typical PD (Iceland)
PARK 11b 2q36-37 unknown genetic susceptibility typical PD
NAc 1q21 GBA/glucocerebrosidase genetic susceptibility typical PD, Ashkenazi Jews
FTDP-17d 17q21 MAPT/tau 1. AD 1. parkinsonism associated with
FTDd
2. genetic susceptibilityb 2. typical PD
SCA2 12q24 ATXN2/ataxin-2 AD rare cause of PD (China)
SCA3 14q24.3-q31 ATXN3/ataxin-3 AD rare cause of PD (Africa)
NA 2q22-23 NR4A2/NURR1b unknown typical PD (European descent)
NA 5q23.1-23.3 SNCAIP/synphilin-1b unknown typical PD (Germany)
Note: PARK4 and PARK9 were subsequently found not to be genetic loci for PD.
aLow penetrance.
bProvisional analysis.
cNot applicable.
dFTD, frontotemporal dementia; FTDP-17, frontotemporal dementia with parkinsonism linked to chromosome 17; AD, autosomal dominant;
AR, autosomal recessive.The mechanism whereby α-synuclein leads to neuro- n
mdegeneration is unclear, although several possibilities
have been proposed (Cookson, 2005). And, despite an l
menormous amount of work, the normal function of
α-synuclein is not well understood. Thus, α-synuclein i
(localizes to the presynaptic terminal and, by virtue of
its binding properties to lipid membranes, it has been m
cimplicated in synapse function, including synaptic turn-
over. Since Lewy body pathology is composed of fibril- l
rlar α-synuclein and several autosomal-dominant mu-
tations in SNCA lead to enhanced rates of protein c
efibrillization, this conformational change in the structure
of α-synuclein may render it neurotoxic. Others have l
mproposed that small, prefibrillar oligomers of α-synu-
clein are the toxic species leading to neuron dysfunc- t
otion and degeneration. Conversely, the sequestration of
this synaptic protein into inclusions may result in the p
aloss of a critical biological function leading to cell toxic-
ity. Finally, the sequestration of α-synuclein may be n
tneuroprotective and, thus, only indirectly related to dis-
ease pathogenesis. Irrespective of the mechanism of c
bpathogenesis, there is increasing evidence implicating
increased expression of α-synuclein in the pathogene- m
usis of both familial and sporadic PD. Thus, duplication
and triplication of SNCA leads to a gene dose-depen- L
dent increase in disease severity and/or decrease in
age of onset (Singleton and Gwinn-Hardy, 2004). Fur- t
2thermore, genetic polymorphisms in the SNCA gene
may be a risk factor for sporadic PD by increasing the t
iexpression of α-synuclein.
However, the story of PD does not end with α-synu- P
tclein. Numerous additional genetic loci were implicated
in kindreds with familial PD, and the identification of s
yother affected genes has highlighted the view that the
Lewy body is not a pathological hallmark of all forms of teurodegenerative parkinsonism, thereby implying that
ultiple mechanisms may converge to result in a PD-
ike phenotype (Table 1). For example, loss-of-function
utations in the PARK2 (parkin) gene were reported
n 1998 in autosomal-recessive juvenile parkinsonism
ARJP) (Kitada et al., 1998). While most ARJP patients
anifest features characteristic of Lewy body PD, in-
luding L-dopa-responsive parkinsonism, neuropatho-
ogical evaluation of their brains typically reveals neu-
on loss and gliosis in the substantia nigra and locus
eruleus, but no Lewy bodies (Cookson, 2005). Parkin
ncodes for an E3 protein ubiquitin ligase, which regu-
ates a key step in the proteolysis of damaged and/or
isfolded proteins that are subsequently degraded by
he proteasome, a process implicated in a wide variety
f neurodegenerative diseases. By implication, loss of
arkin function, as observed in ARJP, may lead to the
ccumulation of one or more of its substrates that are
eurotoxic, including synphilin-1, that may directly in-
eract with α-synuclein (Chung et al., 2001). And re-
ently, parkin was demonstrated to be nitrosylated in
oth sporadic PD patients as well as several animal
odels of PD, and this molecular modification may reg-
late parkin function, further suggesting a link between
ewy body PD and ARJP (Chung et al., 2004).
Subsequently, pathogenic autosomal-recessive mu-
ations were identified in PARK7 (DJ1) (Bonifati et al.,
003) and PINK1 (Valente et al., 2004) that were linked
o the PARK7 and PARK6 locus, respectively. The clin-
cal phenotype of patients with mutations in DJ1 and
INK1 are similar to ARJP, with onset typically younger
han 40 years, a slow disease course, and good re-
ponse to L-dopa therapy. However, pathology is not
et available on patients with either mutation. In con-
rast to parkin, the functions of DJ1 and Pink1 are less
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481Figure 1. Molecular Genetic Neuropathology of Parkinson’s
Disease
Algorithm for the neuropathologic differential diagnosis of patients
with PD. Neuropathologic examination of the majority of patients with
L-dopa-responsive parkinsonism reveals α-synuclein-positive Lewy
body pathology (indicated in blue). However, neuropathologic eval-
uation cannot readily distinguish those patients with concurrent
dementia (i.e., PDD or DLB). In addition, a subset of parkinsonian
patients will have α-synuclein-positive glial cytoplasmic inclusions
indicative of multiple system atrophy while other patients will have
tau pathology (±senile plaques). There is limited neuropathologic
data on patients with many of the newly described mutations.
Moreover, this algorithm represents an oversimplification and does
not reflect other disorders that may also present with parkinsonism.
AD, Alzheimer’s disease; CBD, corticobasal degeneration; DLB, de-
mentia with Lewy bodies; FTDP-17, frontotemporal dementia with
parkinsonism linked to chromosome 17; GCI, glial cytoplasmic in-
clusions; LBVAD, Lewy body variant of Alzheimer’s disease; MSA,
multiple system atrophy; PD, Parkinson’s disease; PDD, Parkin-
son’s disease dementia; PSP, progressive supranuclear palsy.well-defined. DJ-1 was initially identified as a stabilizer
of mRNA. More recently, studies have suggested that
loss of DJ-1 function sensitizes neurons to oxidative
stress and/or proteasomal inhibition that may impact
mitochondrial function (Cookson, 2005). PINK1 is a ser-
ine/threonine protein kinase containing an amino-ter-
minal mitochondrial localization signal that may protect
cells against apoptosis induced by cell stress (Valente
et al., 2004). Thus, mutations in both DJ-1 and PINK1
may cause mitochondrial dysfunction, thereby contrib-
uting to nigrostriatal degeneration, as suggested by
two animal models of PD that are generated by the
treatment of rodents with either MPTP or rotenone.
More recently, two groups reported autosomal-domi-
nant mutations in the LRRK2 gene, which mapped to
the PARK8 locus (Paisan-Ruiz et al., 2004; Zimprich et
al., 2004). Patients in these kindreds present with L-dopa-
responsive parkinsonism often associated with demen-
tia or amyotrophy or both. While all autopsied patients
exhibited degeneration of the substantia nigra, the
pathology showed remarkable heterogeneity with a
variety of different inclusions in distinct individuals, in-
cluding Lewy body pathology, tau pathology, or ubiq-
uitin-positive (tau and α-synuclein negative) filamen-
tous lesions similar to the inclusions described in a
large subset of patients who present clinically with
frontotemporal dementia (McKhann et al., 2001). Aswith most of the genes described above, the function
of LRRK2 is unknown, although it contains a number of
well-defined domains, including Ras/GTPase, tyrosine
kinase, WD40, and leucine-rich-repeat domains. Of
note, the most common mutation identified to date,
G2019S, is located within a critical region of the kinase
domain. Moreover, the clinical and neuropathological
phenotypic variability associated with LRRK2 muta-
tions suggests that these mutations affect a common
neurotoxic pathway.
Mutations in SNCA, parkin, DJ-1, PINK1, and LRRK2
are all associated with relatively rare forms of familial
PD. In contrast, heterozygous mutations were recently
identified in the GBA (glucocerebrosidase) gene as a
significant genetic risk factor for the development of
otherwise typical Lewy body PD in Ashkenazi Jews
(Aharon-Peretz et al., 2004). Of note, homozygous or
compound heterozygous mutations in the GBA gene
cause the autosomal-recessive disorder Gaucher’s dis-
ease. It has recently been appreciated that patients
with Gaucher’s disease often manifest parkinsonism or,
occasionally, features of typical Lewy body PD. While
the carrier frequency of GBA mutations in the Ashke-
nazi population may be as high as 10%, the signifi-
cance of GBA alterations to Lewy body PD in other
populations is unclear. Interestingly, the pathology of
patients with GBA mutations, where available, shows
at least some Lewy body pathology in over 80% of pa-
tients analyzed (Lwin et al., 2004). α-synuclein binds
lipid membranes, and recent work has suggested that
lipids may be a critical modulator of α-synuclein toxic-
ity (Welch and Yuan, 2003). Thus, mutations in GBA
may alter membrane lipid composition by an increase
in phosphatidylcholine content, a neutral phospholipid.
Since α-synuclein binds neutral lipids less avidly, this
alteration in membrane composition could lead to an
increase in free cytosolic α-synuclein similar to that
caused by gene duplication.
The remarkable discoveries that multiple genes are
pathogenic for PD and other PD-like neurodegenerative
movement disorders implies that more than one dis-
ease pathway results in the degeneration of extrapy-
ramidal motor system neurons. Nonetheless, several
models have been proposed that attempt to integrate
some or all of these genetic alterations (Cookson, 2005;
Feany, 2004; Greenamyre and Hastings, 2004). Indeed,
these provocative discoveries provide novel opportuni-
ties to generate informative animal models and acceler-
ate the pace of research into the causes and treatments
of these diverse neurodegenerative movement disor-
ders. However, this will be a challenging task because
it now is clear that pathogenically diverse disorders
cause degeneration of extrapyramidal motor system
neurons that is manifested clinically by the features of
classic PD, but many of these disorders either lack
Lewy bodies or are characterized by filamentous inclu-
sions formed by proteins other than α-synculein. Add-
ing to this phenotypic complexity is the frequent cooc-
currence of different filamentous inclusions in the same
patient, as exemplified by Lewy bodies and filamentous
tau inclusions that are hallmark lesions of other neuro-
degenerative movement disorders such as progressive
supranuclear palsy. Although the reasons for this are
enigmatic, tau and α-synuclein synergistically promote
Neuron
482Sthe fibrillization of each other in vitro, while the over-
expression of mutant human α-synuclein in transgenic
Amice induces the formation of filamentous tau inclu-
N
sions as well as abundant Lewy body-like pathology
B
(Giasson et al., 2003). This is remarkably similar to the K
cooccurrence of abundant tau tangles and α-synuclein (
Lewy bodies in the brains of patients with familial PD C
caused by the same mutation in the SNCA gene (Kotz- R
bauer et al., 2004). These findings emphasize the need 1
to improve our current understanding of the interac- C
Mtions of amyloidogenic brain polypeptides in diverse
1neurodegenerative movement disorders, and they also
Csuggest the tantalizing possibility that therapeutic
Fagents designed to inhibit or reverse the fibrillization of
one disease protein might have similar effects on other G
amyloidogenic brain proteins. G
KSince degeneration of the substantia nigra is com-
3mon to all forms of parkinsonism, but Lewy body pa-
Gthology is only present in a subset of parkinsonian dis-
1orders, parkinsonism is a clinical entity reflective of
Hnigrostriatal degeneration that results from diverse un-
1derlying mechanisms and pathologies. If Lewy bodies
Kdefine only classic PD, is there a unifying nosology for
MLewy body PD that integrates this classical movement
tdisorder with current concepts of other forms of neuro-
Kdegenerative parkinsonism? The answer to this ques-
T
tion is obviously complex, and it is likely to evolve over 2
time as new insights into parkinsonian disorders con-
K
tinue to emerge. However, a reasonable model for a P
new nosology of these disorders is the one proposed G
recently for frontotemporal dementia, which acknowl- L
edged that a variety of disease mechanisms lead to a d
Gcommon clinical phenotype, as is the case with neuro-
degenerative parkinsonian disorders (McKhann et al., L
s2001). Thus, since Lewy body PD was initially defined
Mas a clinical entity, this nomenclature should be re-
atained while acknowledging that a variety of disease
Pmechanisms and attendant pathologies associated
dwith nigrostriatal degeneration can underlie diverse
aforms of PD (Figure 1). While Lewy body pathology is
Pby far the most common hallmark brain lesion linked to
wnigrostriatal degeneration, other pathologies, including
Pα-synuclein-positive glial cytoplasmic inclusions and
Dtangles formed by filamentous tau aggregates, also un-
S
derlie the same clinical phenotype, i.e., progressive
S
parkinsonism with and without associated manifesta-
Stions (e.g., dementia, autonomic failure). A rational no-
K
sology for parkinsonian disorders linked to their molec- e
ular and genetic underpinnnings is not only critical to S
facilitating mechanistically based drug discovery ef- J
forts, but it also will promote the informed design of V
animal models of each form of parkinsonism as well as K
efforts to dissect out how genetic and environmental e
factors differentially contribute to these disorders. Fur- W
ther, while there may be overlap in the pathogenesis of Z
different forms of parkinsonism (Feany, 2004; Greenamyre R
aand Hastings, 2004), it is timely to replace a 19th Cen-
tury descriptive view of PD with a more rational nosol- Z
Sogy tied to genetic and molecular mechanisms of ni-
Ngrostriatal neurodegeneration.
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